Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor in Remote Ischemic Preconditioning Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Hellenic Society of Interventional Cardiology
- Target Recruit Count
- 245
- Registration Number
- NCT04174261
- Locations
- 🇬🇷
Athens Red Cross Hospital, Athens, Attica, Greece
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 26
- Registration Number
- NCT04091074
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Region Skane
- Registration Number
- NCT04069234
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 90
- Registration Number
- NCT04006288
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Platelet Sub-study of the TWILIGHT Trial
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Juan Badimon
- Target Recruit Count
- 40
- Registration Number
- NCT04001374
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2023-04-13
- Target Recruit Count
- 72
- Registration Number
- NCT03869268
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom
SAPT Versus DAPT in Incomplete Revascularization After CABG
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Campus Bio-Medico University
- Target Recruit Count
- 800
- Registration Number
- NCT03789916
- Locations
- 🇮🇹
Università Campus Bio-Medico di Roma, Rome, Italy
Chewed Versus Integral Pill of Ticagrelor
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT03708588
- Locations
- 🇺🇸
Aurora Health Care, St. Luke's Medical Center, Milwaukee, Wisconsin, United States
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 193
- Registration Number
- NCT03615924
- Locations
- 🇬🇧
Research Site, London, United Kingdom
The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT03577652
- Locations
- 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.